​

Lantheus (LNTH) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Lantheus Revenue Highlights

Latest Revenue (Y)

$1.30B

Latest Revenue (Q)

$378.73M

Main Segment (Y)

Product

Main Geography (Y)

US Segment

Lantheus Revenue by Period

Lantheus Revenue by Year

DateRevenueChange
2023-12-31$1.30B38.65%
2022-12-31$935.06M119.91%
2021-12-31$425.21M25.28%
2020-12-31$339.41M-2.28%
2019-12-31$347.34M1.15%
2018-12-31$343.37M3.62%
2017-12-31$331.38M9.78%
2016-12-31$301.85M2.86%
2015-12-31$293.46M-2.70%
2014-12-31$301.60M6.32%
2013-12-31$283.67M-1.54%
2012-12-31$288.11M-19.14%
2011-12-31$356.29M-

Lantheus generated $1.30B in revenue during NA 2023, up 38.65% compared to the previous quarter, and up 377.56% compared to the same period a year ago.

Lantheus Revenue by Quarter

DateRevenueChange
2024-09-30$378.73M-3.90%
2024-06-30$394.09M6.52%
2024-03-31$369.98M4.51%
2023-12-31$354.00M10.64%
2023-09-30$319.95M-0.55%
2023-06-30$321.70M6.95%
2023-03-31$300.78M14.29%
2022-12-31$263.17M9.98%
2022-09-30$239.29M6.96%
2022-06-30$223.72M7.11%
2022-03-31$208.88M61.22%
2021-12-31$129.56M26.93%
2021-09-30$102.07M1.00%
2021-06-30$101.06M9.25%
2021-03-31$92.51M-1.75%
2020-12-31$94.15M6.33%
2020-09-30$88.54M34.14%
2020-06-30$66.01M-27.22%
2020-03-31$90.70M1.52%
2019-12-31$89.35M4.16%
2019-09-30$85.78M0.08%
2019-06-30$85.70M-0.93%
2019-03-31$86.51M0.28%
2018-12-31$86.27M-2.96%
2018-09-30$88.90M3.89%
2018-06-30$85.57M3.56%
2018-03-31$82.63M1.71%
2017-12-31$81.24M1.63%
2017-09-30$79.94M-10.01%
2017-06-30$88.84M9.19%
2017-03-31$81.36M9.43%
2016-12-31$74.35M1.76%
2016-09-30$73.06M-6.29%
2016-06-30$77.97M1.95%
2016-03-31$76.47M7.41%
2015-12-31$71.20M-3.94%
2015-09-30$74.12M1.10%
2015-06-30$73.31M-2.02%
2015-03-31$74.82M-2.79%
2014-12-31$76.97M1.70%
2014-09-30$75.68M0.09%
2014-06-30$75.61M3.10%
2014-03-31$73.34M2.33%
2013-12-31$71.67M1.82%
2013-09-30$70.39M-0.31%
2013-06-30$70.60M-0.59%
2013-03-31$71.02M-

Lantheus generated $378.73M in revenue during Q3 2024, up -3.90% compared to the previous quarter, and up 117.73% compared to the same period a year ago.

Lantheus Revenue Breakdown

Lantheus Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
PYLARIFY$851.30M$527.40M$43.41M--
Product$1.26B----
Total Precision Diagnostics$390.12M$356.68M$351.02M--
Techne Lite$87.37M$88.86M$91.29M--
Other Precision Diagnostics$22.98M$22.82M$26.97M--
License and Royalty Revenues$33.36M$48.02M$24.85M--
DEFINITY$279.77M$244.99M$232.76M--
Radiopharmaceutical Oncology$854.43M$531.51M$48.89M--
Strategic Partnerships And Other$51.88M$46.87M$25.30M--
Other Radiopharmaceutical Oncology$3.13M$4.10M$5.47M--
Product Revenue, Net-$887.04M$400.36M--
US Segment---$294.80M$303.99M
International Segment---$44.61M$43.35M

Lantheus's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (32.91%), Radiopharmaceutical Oncology (22.27%), PYLARIFY (22.18%), Total Precision Diagnostics (10.17%), DEFINITY (7.29%), Techne Lite (2.28%), Strategic Partnerships And Other (1.35%), License and Royalty Revenues (0.87%), Other Precision Diagnostics (0.60%), and Other Radiopharmaceutical Oncology (0.08%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Techne Lite$20.48M$28.19M$21.71M$23.27M$21.59M$20.99M$24.73M$22.09M$19.44M$22.61M$22.04M$22.68M$23.77M$22.80M------
Total Precision Diagnostics$103.73M$112.11M$104.21M$96.35M$97.58M$95.62M$94.37M$89.01M$87.11M$86.20M$87.04M$87.88M$90.36M$85.75M------
DEFINITY$76.97M$78.10M$76.56M$67.34M$70.53M$68.82M$63.62M$60.74M$62.31M$58.33M$59.31M$57.64M$59.84M$55.97M------
License and Royalty Revenues$4.13M$1.33M$662.00K$438.00K$7.62M$8.53M$7.29M$5.93M$5.94M$28.87M$6.76M$5.39M$7.50M$5.19M------
Other Precision Diagnostics$6.28M$5.83M$5.93M$5.74M$5.45M$5.81M$6.02M$6.17M$5.36M$5.26M$5.68M$7.56M$6.74M$6.98M------
PYLARIFY$259.76M$273.25M$258.87M$215.43M$210.52M$195.47M$160.64M$143.75M$130.23M$92.78M----------
Product$374.60M$392.76M$369.31M$319.51M$314.08M$292.26M$233.37M$217.78M$180.01M$96.68M$93.56M$87.32M--------
Radiopharmaceutical Oncology$259.76M$273.25M$259.25M$216.28M$211.34M$196.19M$161.56M$144.68M$131.16M$94.10M$35.68M$8.89M$2.81M$1.50M------
Strategic Partnerships And Other$15.25M$8.72M$6.51M$7.32M$12.78M$8.98M$7.24M$5.60M$5.45M$28.58M$6.84M$5.30M$7.90M$5.25M------
Other Radiopharmaceutical Oncology--$384.00K$848.00K$818.00K$717.00K$919.00K$928.00K$928.00K$1.33M----------
International Segment--------------$12.97M$11.07M$8.61M$11.96M$10.63M$11.13M
US Segment--------------$81.18M$77.47M$57.40M$78.75M$78.72M$74.65M

Lantheus's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (33.42%), PYLARIFY (23.17%), Radiopharmaceutical Oncology (23.17%), Total Precision Diagnostics (9.25%), DEFINITY (6.87%), Techne Lite (1.83%), Strategic Partnerships And Other (1.36%), Other Precision Diagnostics (0.56%), and License and Royalty Revenues (0.37%).

Lantheus Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 20Dec 19Dec 18
US Segment$294.80M$72.53M-
Worldwide-$347.34M-
UNITED STATES--$288.58M
All Other--$54.79M

Lantheus's latest annual revenue breakdown by geography, as of Dec 20: US Segment (100.00%).

Quarterly Revenue by Country

CountryDec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Dec 18Sep 18Jun 18Mar 18
US Segment$81.18M$77.47M$57.40M$19.36M$78.72M$74.65M$75.19M$75.43M$72.75M$70.25M$74.09M$71.49M

Lantheus's latest quarterly revenue breakdown by geography, as of Dec 20: US Segment (100.00%).

Lantheus Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RDYDr. Reddy's Laboratories$279.16B-
CTLTCatalent$4.38B$1.02B
NBIXNeurocrine Biosciences$1.89B$622.10M
ALKSAlkermes$1.66B$378.14M
LNTHLantheus$1.30B$378.73M
PCRXPacira BioSciences$674.98M$168.57M
AMPHAmphastar Pharmaceuticals$593.24M$188.82M
COLLCollegium Pharmaceutical$566.77M$159.30M
ANIPANI Pharmaceuticals$486.82M$148.33M
IRWDIronwood Pharmaceuticals$442.74M$91.59M
DVAXDynavax$232.28M$79.34M
DERMJourney Medical$79.18M$14.86M
AQSTAquestive Therapeutics$50.58M$13.54M
AVDLAvadel Pharmaceuticals$27.96M$50.02M

LNTH Revenue FAQ

What is Lantheus’s yearly revenue?

Lantheus's yearly revenue for 2023 was $1.3B, representing an increase of 38.65% compared to 2022. The company's yearly revenue for 2022 was $935.06M, representing an increase of 119.91% compared to 2021. LNTH's yearly revenue for 2021 was $425.21M, representing an increase of 25.28% compared to 2020.

What is Lantheus’s quarterly revenue?

Lantheus's quarterly revenue for Q3 2024 was $378.73M, a -3.90% decrease from the previous quarter (Q2 2024), and a 18.37% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $394.09M, a 6.52% increase from the previous quarter (Q1 2024), and a 22.50% increase year-over-year (Q2 2023). LNTH's quarterly revenue for Q1 2024 was $369.98M, a 4.51% increase from the previous quarter (Q4 2023), and a 23.00% increase year-over-year (Q1 2023).

What is Lantheus’s revenue growth rate?

Lantheus's revenue growth rate for the last 3 years (2021-2023) was 204.89%, and for the last 5 years (2019-2023) was 273.25%.

What are Lantheus’s revenue streams?

Lantheus's revenue streams in c 23 are PYLARIFY, Product, Total Precision Diagnostics, Techne Lite, Other Precision Diagnostics, License and Royalty Revenues, DEFINITY, Radiopharmaceutical Oncology, Strategic Partnerships And Other, and Other Radiopharmaceutical Oncology. PYLARIFY generated $851.3M in revenue, accounting 22.18% of the company's total revenue, up 61.41% year-over-year. Product generated $1.26B in revenue, accounting 32.91% of the company's total revenue Total Precision Diagnostics generated $390.12M in revenue, accounting 10.17% of the company's total revenue, up 9.37% year-over-year. Techne Lite generated $87.37M in revenue, accounting 2.28% of the company's total revenue, down -1.68% year-over-year. Other Precision Diagnostics generated $22.98M in revenue, accounting 0.60% of the company's total revenue, up 0.68% year-over-year. License and Royalty Revenues generated $33.36M in revenue, accounting 0.87% of the company's total revenue, down -30.53% year-over-year. DEFINITY generated $279.77M in revenue, accounting 7.29% of the company's total revenue, up 14.19% year-over-year. Radiopharmaceutical Oncology generated $854.43M in revenue, accounting 22.27% of the company's total revenue, up 60.76% year-over-year. Strategic Partnerships And Other generated $51.88M in revenue, accounting 1.35% of the company's total revenue, up 10.68% year-over-year. Other Radiopharmaceutical Oncology generated $3.13M in revenue, accounting 0.08% of the company's total revenue, down -23.70% year-over-year.

What is Lantheus’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Lantheus was Product. This segment made a revenue of $1.26B, representing 32.91% of the company's total revenue.